Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
The current price of SERA is $1.88 USD — it has decreased by -1.05% in the past 24 hours. Watch Sera Prognostics stock price performance more closely on the chart.
What is Sera Prognostics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sera Prognostics stocks are traded under the ticker SERA.
Is Sera Prognostics stock price growing?▼
SERA stock has fallen by -5.53% compared to the previous week, the month change is a -18.26% fall, over the last year Sera Prognostics has showed a -25.4% decrease.
What is Sera Prognostics market cap?▼
Today Sera Prognostics has the market capitalization of 70.74M
What is Sera Prognostics revenue for the last year?▼
Sera Prognostics revenue for the last year amounts to 154,000 USD.
What is Sera Prognostics net income for the last year?▼
SERA net income for the last year is -67.4M USD.
How many employees does Sera Prognostics have?▼
As of May 06, 2026, the company has 63 employees.
In which sector is Sera Prognostics located?▼
Sera Prognostics operates in the Health & Wellness sector.
When did Sera Prognostics complete a stock split?▼
Sera Prognostics has not had any recent stock splits.
Where is Sera Prognostics headquartered?▼
Sera Prognostics is headquartered in Salt Lake City, United States.